Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, 27599, USA.
Expert Rev Hematol. 2013 Feb;6(1):91-101. doi: 10.1586/ehm.12.74.
Microvesicles (MVs) are small (0.1-1 µm) membrane vesicles released from activated cells. The surface of MVs can be highly procoagulant due to the presence of the procoagulant protein tissue factor (TF) and of negatively charged phospholipids, such as phosphatidylserine. This review focuses on the potential utility of plasma MVs as a biomarker of venous thrombosis. The majority of studies have not found a clear relationship between venous thrombosis and phosphatidylserine-positive MVs or platelet MVs. Conversely, TF-positive MVs are increased in patients with venous thromboembolism. Studies with pancreatic cancer patients suggest that elevated levels of TF-positive MVs may be predictive of the development of venous thrombosis and patient survival. However, further studies are needed to determine if TF-positive MVs are a good biomarker for venous thrombosis in cancer and other diseases.
微囊泡 (MVs) 是从激活的细胞中释放的小 (0.1-1 µm) 膜囊泡。由于存在促凝蛋白组织因子 (TF) 和带负电荷的磷脂,如磷脂酰丝氨酸,MVs 的表面具有高度促凝性。本综述重点介绍了血浆 MVs 作为静脉血栓形成生物标志物的潜在用途。大多数研究并未发现静脉血栓形成与磷脂酰丝氨酸阳性 MVs 或血小板 MVs 之间存在明确关系。相反,TF 阳性 MVs 在静脉血栓栓塞症患者中增加。对胰腺癌患者的研究表明,TF 阳性 MVs 水平升高可能预示着静脉血栓形成和患者生存。然而,还需要进一步的研究来确定 TF 阳性 MVs 是否是癌症和其他疾病中静脉血栓形成的良好生物标志物。